CT abstracts investigational trajectories and output (n = 393). (A) Distribution of the CT according to their highest clinical phase reached. (B) Proportion of drug approval vs not of the trials according to their earliest phase presented in the study period. (C) Approval rates of CT by type of leukemia. χ2; P < .05 indicates statistical significance. (D) Spatial distribution of abstracts based on the countries where the studies were conducted. Europe is represented as a single entity on the world map and shown in more detail in the zoomed-in view. (E) Proportion of abstracts that reached or not the regulatory approval by continent. (F) Trajectory of the trials including at least 1 site in the United States across the phases according to their earliest phase captured in the study period. (G) Distribution of the CTs according to the availability of the publication as full-length manuscripts. (H) Correlation of the journal's impact factor with drug approval resulting from the CT. Spearman correlation test; P < .05 indicates statistical significance. (I) Top 5 journals reporting the trials that led to approvals and those that did not. Bubble sizes are proportional to the impact factor of the journal. Impact factor: 2023 Journal Citation Reports (JCR) by Clarivate. ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; FDA, US Food and Drug Administration.
